Here are four things to know about the survey, which was launched in May:
- About 5 percent of survey participants reported spending more than $5,000 a month on cancer drugs. More than 10 percent reported spending between $1,000 and $4,999 a month.
- Nearly 20 percent of respondents or their family members have been living with cancer for more than 10 years.
- Approximately 35 percent of respondents said they receive financial support from an assistance program.
- Around 9 percent of participants reported being denied assistance.
More articles on cancer drugs:
Why this cancer drug is being fast-tracked for FDA approval
Protestors at ‘right to try’ rally in D.C. want access to experimental drugs
Novartis pledges to triple biosimilar drugs in market by 2020
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
